Molecular Partners (MOLN) Corporate presentation summary

Company overview and financial position

• Clinical-stage biotech focused on DARPin therapeutics, with operations in Switzerland and the US, and $100M in cash as of March 31, 2026.

• Proprietary platforms enable innovation in targeted cancer therapies, leveraging partnerships with global experts.

• Pipeline includes radio-DARPins and next-gen immune cell engagers, with early clinical readouts targeting high unmet needs.

DARPin technology and innovation

• DARPin therapeutics offer high tumor selectivity, low immunogenicity, and deep tumor penetration due to small size.

• Radio-DARPins act as isotope-agnostic vectors, enabling precise delivery of potent radioisotopes for solid tumors.

• Flexibility in chelator and isotope selection allows parallel evaluation of 212Pb and 225Ac for optimal therapeutic effect.

Clinical pipeline and development progress

• MP0712 (DLL3-targeted) in Phase 1/2a for SCLC and neuroendocrine cancers, with strong tumor uptake and favorable biodistribution in early human imaging.

• MP0726 (MSLN-targeted) advancing to first-in-human imaging for ovarian cancer, maintaining binding despite shed MSLN.

• Additional programs include next-gen immune cell engagers and switch-DARPins, with multiple candidates in preclinical and clinical stages.